Suppr超能文献

酚妥拉明-氧烯洛尔或拉贝洛尔(AH 5158)联合α和β肾上腺素能受体阻滞剂的抗高血压疗效。

The anti-hypertensive efficacy of combined alpha- and beta-adrenoreceptor blockade with phentolamine-oxprenolol or with labetalol (AH 5158).

作者信息

Johnson B F, LaBrooy J, Munro-Faure A D

出版信息

Clin Sci Mol Med Suppl. 1976 Dec;3:505s-507s.

PMID:799558
Abstract
  1. The interaction of phentolamine with the beta-receptor blocker oxprenolol was studied in a controlled trial. 2. The combination was generally well tolerated. 3. Oxprenolol alone produced modest but significant reductions in supine, standing and post-exercise blood pressures. Small reductions were seen only with sustained phentolamine administration. 4. The combined effect of the two drugs appeared to be additive only at the lower doses of oxprenolol. 5. Labetalol produced significantly greater reductions in supine and standing blood pressure than combined oxprenolol-phentolamine. At a daily dose of 400 mg, postural hypotension was not seen, though transient symptoms were frequent.
摘要
  1. 在一项对照试验中研究了酚妥拉明与β受体阻滞剂氧烯洛尔的相互作用。2. 该联合用药总体耐受性良好。3. 单独使用氧烯洛尔可使仰卧位、站立位及运动后血压适度但显著降低。仅持续给予酚妥拉明时血压有小幅下降。4. 两种药物的联合作用仅在较低剂量的氧烯洛尔时似乎具有相加性。5. 拉贝洛尔使仰卧位和站立位血压降低的幅度显著大于氧烯洛尔 - 酚妥拉明联合用药。每日剂量为400mg时,虽常有短暂症状,但未见体位性低血压。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验